$PHG · KONINKLIJKE PHILIPS NV
Philips reported Q3 2026 revenue of €4.393B with 3% comparable sales growth and an 8% surge in comparable order intake. Adjusted EBITA rose to €569M (13.0% margin, +70bps YoY), while GAAP net income collapsed to €28M due to a €288M Respironics DOJ settlement provision. The company reiterated its full-year 2026 outlook.
- Comparable order intake jumped 8%, driven by strong Diagnosis & Treatment momentum
- Adjusted EBITA margin expanded 70bps to 13.0%, with all business segments improving
- Revenue of €4.393B grew 3% comparable, led by Personal Health (+8%) and Connected Care (+5%)
- Respironics DOJ settlement provision of €288M drove GAAP net income down to just €28M from €187M YoY
- Full-year 2026 outlook reiterated: 3-4.5% comparable sales growth, 13.5-14.0% Adjusted EBITA margin
Extended-hours trading shows PHG at $29.26, up 6.05% vs the regular close of $27.59, as the market rewards the 8% order intake beat and margin expansion while looking past the one-time DOJ provision.
The 8% order intake surge and broad margin expansion signal Philips' turnaround is gaining traction, with the DOJ settlement removing a major legal overhang despite the near-term earnings hit.
Philips' 8% order intake growth and broad-based margin expansion contrast with mixed medtech demand signals, suggesting AI-enabled imaging platforms (Verida, Rembra CT, Alturion ultrasound) are gaining commercial traction ahead of RSNA.
The €288M DOJ settlement provision is subject to final documentation; payment is expected in Q1 2027. The outlook excludes other ongoing Respironics-related proceedings including the US State Attorneys General investigation. China Ultrasound sales declined and macro/geopolitical uncertainty persists.